Shanghai Securities News China SecuritiesNet News (Reporter Zhang Xue) The reporter learned from Sinovac Holdings on October 10 that recently, Beijing Sinovac BiotechQuadrivalent influenza virusThe National Medical Products Administration (NMPA) has approved an expanded age range for the Sinovac quadrivalent influenza vaccine, expanding its coverage to include individuals aged 6-35 months, in addition to those aged 3 years and above. With this expanded age range, the Sinovac quadrivalent influenza vaccine now covers all ages 6 months and older and is currently in use in nearly 20 countries and regions worldwide.
　　Infants and young children aged 6-35 months are at high risk for influenza- related complications. Flu vaccination is the most effective and economical way to prevent influenza and reduce the risk of complications. Furthermore, families are a key venue for influenza transmission. Studies have shown that 26% of influenza infections can be attributed to transmission within the family, and the influenza transmission rate between family members is as high as 38%.
　　Experts from the Chinese Center for Disease Control and Prevention recommend that the components of the influenza vaccine will be adjusted annually based on the prevalent strains, and timely vaccination is the only way to effectively match protection needs. It is recommended to complete influenza vaccination before the end of October to ensure effective immune protection before the peak of the influenza epidemic. Especially for high-risk groups, early vaccination is the key to protecting health.

https://finance.eastmoney.com/a/202510103530964691.html